Prep­ping for key ASH pre­sen­ta­tion, lit­tle Aprea Ther­a­peu­tics gets $57M to fu­el PhI­II p53 can­cer study

Sev­en months ago, Stock­holm-based Aprea Ther­a­peu­tics man­aged to re­main al­most com­plete­ly over­looked at AACR when the biotech un­veiled da­ta from a hand­ful of 8 pa­tients with TP53 Mu­tant Myelodys­plas­tic Syn­dromes. Sci­en­tists said the study demon­strat­ed a 100% over­all re­sponse rate for their p53 cor­rec­tor — APR-246 com­bined with azac­i­ti­dine.

Six of the pa­tients had a com­plete re­sponse ac­cord­ing to in­ves­ti­ga­tors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.